CRVO vs CTOR

CervoMed Inc. vs Citius Oncology, Inc. — Valuation Comparison 2026

CRVO

Pharmaceutical Preparations
CervoMed Inc.
Quality
4.8
out of 10
Value Trap
33
LOW
Price
$3.11
Last close
Models
9/13
Active
VS

CTOR

Pharmaceutical Preparations
Citius Oncology, Inc.
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$0.80
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType CRVO Fair ValueCRVO Upside CTOR Fair ValueCTOR Upside
Bayesian DCF Intrinsic $1.29 -58.6% $0.24 -70.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.36 +8.0% $0.08 -91.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRVO vs CTOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRVO vs CTOR — Which Stock Is More Undervalued?

CRVO scores higher with a 4.8/10 quality rating vs CTOR's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CervoMed Inc. (CRVO) and Citius Oncology, Inc. (CTOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRVO currently trades at $3.11 with a QOC of 4.8/10, while CTOR trades at $0.80 with a QOC of 3.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).